ライフサイエンスコーパス: was not significant

1 tients compared to 6 for controls; however, this difference was not significant.

2 s not (AUC = 0.66), although the difference between methods was not significant.

3 cases of adverse events in pediatric group was low, but it was not significant.

4 In ulcerative colitis, the association was not significant.

5 .3 mm) and similarly for PPD; the difference between groups was not significant.

6 The difference between the mean age of the two groups was not significant.

7 However, this difference was not significant.

8 lacebo (0.25; 95% CI: -0.02, 0.51; P = 0.06), although this was not significant.

9 The adjusted between-group difference was not significant (0.82 percentage points; 95% confidence i

10 t-exposed compared with the nonexposed children, but the HR was not significant (14.59% vs 10.71%; absolute difference, 3

11 e in mortality between the third year and the first 2 years was not significant (-3.6%; 95% CI, -12.3 to 4.5; P = 0.50).

12 months than the ranibizumab group although this difference was not significant (8 vs. 6 injections; P = 0.13).

13 s (2.0%) in the control group; the between-group difference was not significant (adjusted relative risk, 1.13; 95% confid

14 09 [95% CI, 1.05-1.13], P=2.28x10(-5)), but the association was not significant after adjusting for clinical risk factors

15 ispanic patients, although the difference in Black patients was not significant after adjusting for mediating factors.

16 30 days vs 7.3% in the nonuser group, but this association was not significant after adjustment for age, sex, and medica

17 iated with SVR in univariate analysis, but this association was not significant after adjustment for age.

18 sociation of BMI with mortality (HR 0.54, 95% CI 0.31-0.95) was not significant after adjustment for IMDC risk score (adj

19 thickness asymmetry of the superior temporal cortex, which was not significant after adjustment for multiple testing.

20 hiding (d = 0.37) were increased during fireworks, but this was not significant after sequential Bonferroni correction.

21 up; the difference between the converters and nonconverters was not significant, but the PRS was significantly higher in

22 size [ES] = 0.45): the change within the pomegranate group was not significant (ES = 0.15), whereas the placebo group sh

23 t (P < 0.001) and MetS diagnostic criteria (P = 0.043), but was not significant for variables of study type (P = 0.899),

24 Contrary to our hypothesis, the observed effect was not significant; however, it did fall within the 95% conf

25 tion in growth and biomass response among Arabica cultivars was not significant; however, significant trends in leaf area

26 however, the effect on self-efficacy for obtaining respite was not significant (I(2) = 0, SMD = 0.17, 95%CI = -0.16 to 0

27 ard ratio [HR] 2.13 [95% CI 1.49 to 3.02], P < 0.001), this was not significant in multivariable analysis (HR 1.37 [95% C

28 sitivity between QFT-Plus and QFT-GIT in active TB patients was not significant in nearly all studies and ranged from -4.

29 The difference was not significant in the control and IHCC groups.

30 a small effect on mitochondrial density in newborns, which was not significant in this study after adjustment for multip

31 However, the risk for BMI <24.0 kg/m(2) was not significant (OR, 1.47 [0.47 to 4.54]).

32 iate with a diagnosis of microvascular angina although this was not significant (OR, 2.7 [0.9-7.9]; P=0.063).

33 n term between annual average NDVI and APOE epsilon4 status was not significant (OR: 1.04, 95% CI: 0.97, 1.11).

34 the most significant predictor of poor outcomes whereas MIV was not significant [OR, 0.99 (0.99-01.00), p = 0.594].

35 8, ATS: r = 0.63) was slightly higher in ATI but the effect was not significant (p > 0.05).

36 Phylogenetic clustering of ticks to hosts at cluster level was not significant (p > 0.15) but if examined individually 6

37 age, the difference in decline between the 2 treatment arms was not significant (P = .09).

38 Although the test for nonlinearity was not significant (p = 0.09) the association appeared to be

39 association between GCC thinning rate and glaucoma severity was not significant (P = 0.586).

40 The difference in complication rates between the 2 groups was not significant (P = 0.6).

41 Race-by-IAAT interaction was not significant (P = 0.65).

42 timulation type, smoking status, and number of levels fused was not significant (p = 0.93, p = 0.82 and p = 0.65, respect

43 chronic limb-threatening ischemia, the mortality difference was not significant; paclitaxel (12.8%) versus nonpaclitaxel

44 There was not significant reduction of periviable mortality between

45 134 (34%) in 395 patients given placebo, a difference that was not significant: relative risk 0.90 (97.8% CI 0.72, 1.15;

46 iables, ranging from surveys for which the diversity effect was not significant to surveys where a significant 80% increa

47 n was observed in favor of HIV-1/M at W48 and W96, but this was not significant when adjusted on both matched criteria an

48 month difference in eGFR between the HMPO(2) and HMP groups was not significant when both kidneys from the same donor wer

49 rs compared to very unhealthy score, though the association was not significant, whilst a healthy score was significantly

50 LT (r = -0.137; P = .002) and LD (r = 0.268; P < .001), it was not significant with LV (r = 0.084; P = .15).